Coverage
-
March 17, 2022
A month after AstraZeneca's Alexion Pharmaceuticals settled claims that its antibody product Ultomiris infringed patents held by Roche-owned rival Chugai Pharmaceutical Co. Ltd., Chugai's attorneys said Thursday the settlement netted their client $775 million.
4 other articles on this case.
View all »